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Background: Abnormal collagen (COL) and fibronectin expression may occur in the progression of aortic regurgitation (AR) and aortic stenosis 
(AS). Plasma levels of procollagen type I amino terminal propeptides (PINP) and COL I carboxy-terminal telopepetide (ICTP), are thought to 
provide indices of COL I synthesis and degradation, respectively. However, the relation of plasma concentrations of these biomarkers to myocardial 
expression of their respective genes is not known.
Method: Tru-cut biopsies were obtained from the LV free wall from pts with normal LV performance undergoing aortic valve replacement (AVR) for 
isolated, pure AS (n=9) or isolated, pure AR (n=10), and from “control” pts with coronary artery disease (CAD) but no infarction undergoing bypass 
grafting (CABG) (n=7). RNA was prepared and used to synthesize labeled cRNA to probe Affymetrix microarrays (Human Genome U133 Plus 2.0). Tissues 
were stained for fibrillar COL by picrosirius red, and for COL I, COL III and fibronectin by immunohistochemistry. Plasma prepared from aretrial blood 
immediately before the induction of cardioplegia was used to measure PINP, ICTP and fibronectin using commercially available ELISA kits.
Results: Plasma concentrations of PINP were 1.5-fold higher in pts with AR (p=0.05) or AS (p=0.07) compared to CAD controls. ICTP and FN 
concentrations were statistically indistinguishable between diagnoses. Plasma concentrations of PINP, ICTP or FN were unrelated to histological or 
immunocytochemical staining for myocardial COL I or fibronectin; no association was apparent with COL I or fibronectin mRNA, or mRNAs encoding 
any proteins potentially involved in the synthesis or degradation of COL or fibronectin.
Conclusion: Although PINP concentrations are abnormal in plasma samples from pts undergoing AVR for AR or AS compared to pts undergoing 
CABG, the poor correlation with myocardial tissue protein and mRNA concentrations suggest that plasma concentrations may not be due to secretion 
from myocardial tissue or that the relation of secretion to tissue metabolism may be particularly complex. More extensive sampling will be needed to 
resolve these issues.
